Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Coating of "Self” Peptides Protects Nanoparticles from Macrophage Destruction

By BiotechDaily International staff writers
Posted on 05 Mar 2013
Image: Diagram of Macrophage Interaction: Macrophages are immune cell “border guards” that have evolved to eat all sorts of foreign microbes, but they also eat many particles that are intended for therapeutics and imaging. A “Minimal peptide ‘Passport’” attached to the particles provides recognition signals so that the particles are not eaten, thus improving delivery to diseased cells in the body (Photo courtesy of Mary Leonard, Biomedical Art & Design, University of Pennsylvania).
Image: Diagram of Macrophage Interaction: Macrophages are immune cell “border guards” that have evolved to eat all sorts of foreign microbes, but they also eat many particles that are intended for therapeutics and imaging. A “Minimal peptide ‘Passport’” attached to the particles provides recognition signals so that the particles are not eaten, thus improving delivery to diseased cells in the body (Photo courtesy of Mary Leonard, Biomedical Art & Design, University of Pennsylvania).
Nanoparticles coated with peptides derived from the human protein CD47 were protected from uptake and destruction by macrophages in a genetically engineered mouse model system.

The membrane protein CD47 is reportedly a "marker of self" in mice that impedes phagocytosis of “self” molecules by signaling through the phagocyte receptor CD172a. CD47, which is found on almost all mammalian cell membranes, binds to the SIRPa macrophage receptor in humans.

Investigators at the University of Pennsylvania (Philadelphia, USA) used computers to design the smallest peptides from human CD47 (hCD47) that could perform the same function. They then synthesized these peptides and attached them to virus-size particles for intravenous injection into mice that had been genetically engineered to express a CD172a variant compatible with hCD47.

Results published in the February 22, 2013, issue of the journal Science revealed that the coating of “self” peptides delayed macrophage-mediated clearance of the nanoparticles, which promoted persistent circulation that enhanced dye and drug delivery to tumors.

"There may be other molecules that help quell the macrophage response," said senior author Dr. Dennis Discher, professor of chemical and biomolecular engineering at the University of Pennsylvania, "but human CD47 is clearly one that says, "Do not eat me. It can be made cleanly in a machine and easily modified during synthesis in order to attach to all sorts of implanted and injected things, with the goal of fooling the body into accepting these things as self."

Related Links:

University of Pennsylvania



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.